Keywords: Merck KGaA, cladribine, multiple sclerosis, research

New data shows promise for Merck KGaA’s oral multiple sclerosis drug cladribine

Article | 14 September 2009

Print This

A new analysis of data from a clinical trial of Merck KGaA's oral drug cladribine has underscored its potential as ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in